[go: up one dir, main page]

PL1836629T3 - Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu - Google Patents

Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu

Info

Publication number
PL1836629T3
PL1836629T3 PL05817266T PL05817266T PL1836629T3 PL 1836629 T3 PL1836629 T3 PL 1836629T3 PL 05817266 T PL05817266 T PL 05817266T PL 05817266 T PL05817266 T PL 05817266T PL 1836629 T3 PL1836629 T3 PL 1836629T3
Authority
PL
Poland
Prior art keywords
chemotherapy
gene expression
predicting response
expression markers
markers
Prior art date
Application number
PL05817266T
Other languages
English (en)
Inventor
Joffre B. Baker
John L. Bryant
Soonmyung Paik
Steven Shak
Original Assignee
Genomic Health, Inc.
Nsabp Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health, Inc., Nsabp Foundation, Inc. filed Critical Genomic Health, Inc.
Publication of PL1836629T3 publication Critical patent/PL1836629T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05817266T 2004-11-05 2005-11-04 Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu PL1836629T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62548504P 2004-11-05 2004-11-05
PCT/US2005/040238 WO2006052862A1 (en) 2004-11-05 2005-11-04 Predicting response to chemotherapy using gene expression markers
EP05817266.9A EP1836629B1 (en) 2004-11-05 2005-11-04 Predicting response to chemotherapy using gene expression markers

Publications (1)

Publication Number Publication Date
PL1836629T3 true PL1836629T3 (pl) 2020-06-15

Family

ID=35871164

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05817266T PL1836629T3 (pl) 2004-11-05 2005-11-04 Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu

Country Status (11)

Country Link
US (3) US7930104B2 (pl)
EP (1) EP1836629B1 (pl)
JP (1) JP5020088B2 (pl)
AU (1) AU2005304824B2 (pl)
CA (2) CA3061785A1 (pl)
DK (1) DK1836629T3 (pl)
ES (1) ES2778851T3 (pl)
HU (1) HUE051605T2 (pl)
IL (1) IL182929A (pl)
PL (1) PL1836629T3 (pl)
WO (1) WO2006052862A1 (pl)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2005039382A2 (en) * 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA3061785A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US9867530B2 (en) 2006-08-14 2018-01-16 Volcano Corporation Telescopic side port catheter device with imaging system and method for accessing side branch occlusions
DK2081950T3 (da) * 2006-09-21 2013-06-03 Nuclea Biomarkers Llc Med irinotecanbehandling forbundne ekspressionsprofiler
WO2008098086A2 (en) * 2007-02-06 2008-08-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A gene expression profile that predicts ovarian cancer subject response to chemotherapy
CA2680591A1 (en) * 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2008115561A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US10219780B2 (en) 2007-07-12 2019-03-05 Volcano Corporation OCT-IVUS catheter for concurrent luminal imaging
EP2178442B1 (en) 2007-07-12 2017-09-06 Volcano Corporation Catheter for in vivo imaging
US9596993B2 (en) 2007-07-12 2017-03-21 Volcano Corporation Automatic calibration systems and methods of use
EP2228457A1 (en) * 2007-08-16 2010-09-15 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
EP2641978A1 (en) * 2008-05-12 2013-09-25 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
US9090945B2 (en) 2009-12-14 2015-07-28 North Carolina State University Mean DNA copy number of chromosomal regions is of prognostic significance in cancer
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
MX355020B (es) 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
JP5931874B2 (ja) 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US11141063B2 (en) 2010-12-23 2021-10-12 Philips Image Guided Therapy Corporation Integrated system architectures and methods of use
US11040140B2 (en) 2010-12-31 2021-06-22 Philips Image Guided Therapy Corporation Deep vein thrombosis therapeutic methods
WO2013033592A1 (en) 2011-08-31 2013-03-07 Volcano Corporation Optical-electrical rotary joint and methods of use
CA2857191A1 (en) * 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013109690A1 (en) * 2012-01-17 2013-07-25 Myriad Genetics, Inc. Breast cancer prognosis signatures
US9324141B2 (en) 2012-10-05 2016-04-26 Volcano Corporation Removal of A-scan streaking artifact
US10568586B2 (en) 2012-10-05 2020-02-25 Volcano Corporation Systems for indicating parameters in an imaging data set and methods of use
US9478940B2 (en) 2012-10-05 2016-10-25 Volcano Corporation Systems and methods for amplifying light
US9292918B2 (en) 2012-10-05 2016-03-22 Volcano Corporation Methods and systems for transforming luminal images
US9858668B2 (en) 2012-10-05 2018-01-02 Volcano Corporation Guidewire artifact removal in images
US10070827B2 (en) 2012-10-05 2018-09-11 Volcano Corporation Automatic image playback
US9307926B2 (en) 2012-10-05 2016-04-12 Volcano Corporation Automatic stent detection
US9367965B2 (en) 2012-10-05 2016-06-14 Volcano Corporation Systems and methods for generating images of tissue
US20140100454A1 (en) 2012-10-05 2014-04-10 Volcano Corporation Methods and systems for establishing parameters for three-dimensional imaging
US9286673B2 (en) 2012-10-05 2016-03-15 Volcano Corporation Systems for correcting distortions in a medical image and methods of use thereof
US11272845B2 (en) 2012-10-05 2022-03-15 Philips Image Guided Therapy Corporation System and method for instant and automatic border detection
US9840734B2 (en) 2012-10-22 2017-12-12 Raindance Technologies, Inc. Methods for analyzing DNA
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2014080060A1 (es) * 2012-11-23 2014-05-30 Servicio Andaluz De Salud Método para predecir la respuesta al tratamiento con quimioterapia en pacientes con cáncer
EP2931132B1 (en) 2012-12-13 2023-07-05 Philips Image Guided Therapy Corporation System for targeted cannulation
US10942022B2 (en) 2012-12-20 2021-03-09 Philips Image Guided Therapy Corporation Manual calibration of imaging system
CA2895502A1 (en) 2012-12-20 2014-06-26 Jeremy Stigall Smooth transition catheters
US11406498B2 (en) 2012-12-20 2022-08-09 Philips Image Guided Therapy Corporation Implant delivery system and implants
US10939826B2 (en) 2012-12-20 2021-03-09 Philips Image Guided Therapy Corporation Aspirating and removing biological material
CA2895989A1 (en) 2012-12-20 2014-07-10 Nathaniel J. Kemp Optical coherence tomography system that is reconfigurable between different imaging modes
WO2014113188A2 (en) 2012-12-20 2014-07-24 Jeremy Stigall Locating intravascular images
WO2014100606A1 (en) 2012-12-21 2014-06-26 Meyer, Douglas Rotational ultrasound imaging catheter with extended catheter body telescope
CA2895993A1 (en) 2012-12-21 2014-06-26 Jason Spencer System and method for graphical processing of medical data
CA2896004A1 (en) 2012-12-21 2014-06-26 Nathaniel J. Kemp Power-efficient optical buffering using optical switch
CA2896006A1 (en) 2012-12-21 2014-06-26 David Welford Systems and methods for narrowing a wavelength emission of light
US9612105B2 (en) 2012-12-21 2017-04-04 Volcano Corporation Polarization sensitive optical coherence tomography system
US10058284B2 (en) 2012-12-21 2018-08-28 Volcano Corporation Simultaneous imaging, monitoring, and therapy
US10413317B2 (en) 2012-12-21 2019-09-17 Volcano Corporation System and method for catheter steering and operation
JP2016501625A (ja) 2012-12-21 2016-01-21 ジェローム マイ, 可変線密度での超音波撮像
US9486143B2 (en) 2012-12-21 2016-11-08 Volcano Corporation Intravascular forward imaging device
JP2016501623A (ja) 2012-12-21 2016-01-21 アンドリュー ハンコック, 画像信号のマルチ経路処理のためのシステムおよび方法
WO2014138555A1 (en) 2013-03-07 2014-09-12 Bernhard Sturm Multimodal segmentation in intravascular images
US10226597B2 (en) 2013-03-07 2019-03-12 Volcano Corporation Guidewire with centering mechanism
US20140276923A1 (en) 2013-03-12 2014-09-18 Volcano Corporation Vibrating catheter and methods of use
US10638939B2 (en) 2013-03-12 2020-05-05 Philips Image Guided Therapy Corporation Systems and methods for diagnosing coronary microvascular disease
US9301687B2 (en) 2013-03-13 2016-04-05 Volcano Corporation System and method for OCT depth calibration
EP2967488B1 (en) 2013-03-13 2021-06-16 Jinhyoung Park System for producing an image from a rotational intravascular ultrasound device
US11026591B2 (en) 2013-03-13 2021-06-08 Philips Image Guided Therapy Corporation Intravascular pressure sensor calibration
US10292677B2 (en) 2013-03-14 2019-05-21 Volcano Corporation Endoluminal filter having enhanced echogenic properties
US10219887B2 (en) 2013-03-14 2019-03-05 Volcano Corporation Filters with echogenic characteristics
US12343198B2 (en) 2013-03-14 2025-07-01 Philips Image Guided Therapy Corporation Delivery catheter having imaging capabilities
US10426590B2 (en) 2013-03-14 2019-10-01 Volcano Corporation Filters with echogenic characteristics
CN103290134B (zh) * 2013-06-21 2015-04-22 中国农业科学院兰州畜牧与兽药研究所 牛actb基因转录水平荧光定量pcr检测试剂盒
US10450612B2 (en) 2013-11-15 2019-10-22 North Carolina State University Chromosomal assessment to diagnose urogenital malignancy in dogs
US10501806B2 (en) 2014-04-15 2019-12-10 North Carolina State University Chromosomal assessment to differentiate histiocytic malignancy from lymphoma in dogs
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10513738B2 (en) 2014-07-24 2019-12-24 North Carolina State University Method to diagnose malignant melanoma in the domestic dog
CN104263723B (zh) * 2014-09-15 2017-06-06 南京医科大学 一种与原发性肺癌辅助诊断相关的低频高外显性遗传标志物及其应用
CN107077536B (zh) 2014-10-24 2021-09-28 皇家飞利浦有限公司 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性
WO2016062892A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
JP7028763B2 (ja) 2015-08-14 2022-03-02 コーニンクレッカ フィリップス エヌ ヴェ 標的遺伝子発現の数学的モデリングを使用するNFkB細胞シグナリング経路活性の評価
JP6938536B2 (ja) * 2016-04-14 2021-09-22 アカデミア シニカAcademia Sinica 新規のvegfr2コレセプターであるscube2の阻害による、腫瘍血管新生の抑制
EP3464640B1 (en) 2016-05-31 2021-06-30 North Carolina State University Methods of mast cell tumor prognosis and uses thereof
WO2017210117A1 (en) * 2016-06-02 2017-12-07 Board Of Trustees, Southern Illinois University Treatment of endometriosis and niclosamide derivatives
CN110573629B (zh) * 2017-03-30 2024-08-13 伊利诺伊大学理事会 用于诊断早期胰腺癌的方法和试剂盒
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3856933A1 (en) * 2018-09-27 2021-08-04 BioNTech Diagnostics GmbH Predictive and prognostic methods in breast cancer
WO2020092808A1 (en) 2018-10-31 2020-05-07 Regents Of The University Of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
CN113785076B (zh) 2019-05-03 2024-06-11 株式会社递希真 预测癌症预后的方法及其组合物
US20220357328A1 (en) * 2019-09-09 2022-11-10 Oaklabs Gmbh Superior biomarker signature to predict the response of a breast cancer patient to chemotherapy
CN112725444A (zh) * 2020-12-30 2021-04-30 杭州联川基因诊断技术有限公司 一种检测pgr基因表达的引物、探针、试剂盒和检测方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
CA2239692C (en) 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
CA2271783C (en) 1996-11-20 2013-04-16 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2330929A1 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
US6696558B2 (en) 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
AU777096B2 (en) 1999-10-06 2004-09-30 Regents Of The University Of California, The Differentially expressed genes associated with Her-2/neu overexpression
EP1686134A3 (en) 1999-12-01 2006-08-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051661A2 (en) * 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
WO2001055454A1 (en) * 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
WO2001055343A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
WO2001075162A2 (en) * 2000-03-31 2001-10-11 University Of Louisville Research Foundation, Inc. Microarrays to screen regulatory genes
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
MXPA03000575A (es) * 2000-07-21 2004-12-13 Global Genomics Ab Metodos para analisis e identificacion de genes transcritos e impresion dactilar.
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002008262A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-5 proteins and related reagents and methods of use thereof
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
EP1353947A2 (en) 2000-12-08 2003-10-22 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
WO2002057787A2 (en) 2001-01-12 2002-07-25 Yale University Detection of survivin in the biological fluids of cancer patients
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
MXPA03006617A (es) 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
IL157872A0 (en) * 2001-03-12 2004-03-28 Monogen Inc A panel for detecting a generic disease state containing a plurality of probes and using cell-based diagnosis
DK1410011T3 (da) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
AU2003215460A1 (en) 2002-03-28 2003-10-13 Qlt Inc. Cancer associated protein kinases and their uses
EP1900827A3 (en) 2002-05-21 2008-04-16 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005039382A2 (en) * 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2848463A1 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス, インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
CA3061785A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
EP2228457A1 (en) * 2007-08-16 2010-09-15 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
EP2641978A1 (en) * 2008-05-12 2013-09-25 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
WO2011063274A2 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Also Published As

Publication number Publication date
US20060166230A1 (en) 2006-07-27
EP1836629A1 (en) 2007-09-26
US20150079591A1 (en) 2015-03-19
AU2005304824A1 (en) 2006-05-18
US7930104B2 (en) 2011-04-19
US20110178374A1 (en) 2011-07-21
AU2005304824B2 (en) 2011-12-22
HUE051605T2 (hu) 2021-03-01
CA2585571C (en) 2020-01-21
CA2585571A1 (en) 2006-05-18
DK1836629T3 (da) 2020-05-18
IL182929A (en) 2011-11-30
CA3061785A1 (en) 2006-05-18
US8868352B2 (en) 2014-10-21
JP5020088B2 (ja) 2012-09-05
WO2006052862A1 (en) 2006-05-18
EP1836629B1 (en) 2020-03-04
IL182929A0 (en) 2007-09-20
JP2008520192A (ja) 2008-06-19
ES2778851T3 (es) 2020-08-12

Similar Documents

Publication Publication Date Title
IL182929A0 (en) Predicting response to chemotherapy using gene expression markers
IL244249A0 (en) Markers for gene expression predicting response to chemotherapy
PL2319932T5 (pl) Nowe geny odporności na herbicydy
IL177965A0 (en) Human-to computer interfaces
PL1827691T3 (pl) Matryca chromatograficzna
GB0512707D0 (en) Gene expression technique
EP1757686A4 (en) INDUCER OF CELL DEATH
DE602005027253D1 (de) Herbizidresistenz verleihende gene
ZA200704389B (en) Increase in yield by reducing gene expression
IL180619A0 (en) Provision of location information into iri
GB0416830D0 (en) Host cell
GB0407150D0 (en) Distributed computer
AU2013206082B2 (en) Gene expression markers for predicting response to chemotherapy
GB0504389D0 (en) Genetic optimization computer system
GB2427728B (en) Analysis of gene expression data
EP1862801A4 (en) TEST METHOD CARRIED OUT WITH RAPPORTEUR GENE
GB2415208B (en) Drag bit
GB0417107D0 (en) Genes II
GB0428301D0 (en) Resistance genes
GB0408629D0 (en) Gene
GB0605999D0 (en) Predicting Gene Expression Levels
GB0405260D0 (en) Antiviral chemotherapy
GB0409391D0 (en) Gene drivers
GB0508503D0 (en) Genes III
GB0407613D0 (en) Anti-fungal target genes